

Effect of Physical Activity Level on Biomarkers of Inflammation and Insulin Resistance Over 5 Years in Outpatients With Coronary Heart Disease (from the Heart and Soul Study)



Jennifer L. Jarvie, MD^a, Mary A. Whooley, MD^{a,b}, Mathilda C. Regan, MPH^b, Nancy L. Sin, PhD^c, and Beth E. Cohen, MD, MAS^{a,b,*}

Higher levels of physical activity are associated with lower rates of coronary heart disease (CHD). Previous studies have suggested that this is due partly to lower levels of inflammation and insulin resistance. The aim of this study was to determine whether physical activity level was associated with inflammation or insulin resistance during a 5-year period in outpatients with known CHD. A total of 656 participants from the Heart and Soul Study, a prospective cohort study of outpatients with documented CHD, were evaluated. Self-reported physical activity frequency was assessed at baseline and after 5 years of follow-up. Participants were classified as low versus high activity at each visit, yielding 4 physical activity groups: stable low activity, decreasing activity (high at baseline to low at year 5), increasing activity (low at baseline to high at year 5), and stable high activity. Year 5 markers of inflammation (C-reactive protein [CRP], interleukin-6, and fibrinogen) and insulin resistance (insulin, glucose, and glycated hemoglobin) were compared across the 4 activity groups. After 5 years of follow-up, higher activity was associated with lower mean levels of all biomarkers. In the fully adjusted regression models, CRP, interleukin-6, and glucose remained independently associated with physical activity frequency (log CRP, *p* for trend across activity groups = 0.03; log interleukin-6, *p* for trend = 0.01; log glucose, *p* for trend = 0.003). Subjects with stable high activity typically had the lowest levels of biomarkers. In conclusion, in this novel population of outpatients with known CHD followed for 5 years, higher physical activity frequency was independently associated with lower levels of CRP, interleukin-6, and glucose. © 2014 Elsevier Inc. All rights reserved. (Am J Cardiol 2014;114:1192–1197)

To date, most studies examining the effect of physical activity on inflammation or insulin resistance have been limited by cross-sectional designs or short durations. One exception was a prospective study of British adults aged 35 to 55 years, which found that regular physical activity was associated with lower inflammation over a 10-year interval.¹

However, it is unclear whether the results in this younger sample apply to patients with existing coronary heart disease (CHD). Patients with CHD may be less likely to participate in more vigorous physical activity, which may attenuate the effect of physical activity on biomarker levels. In addition, medications such as statins, which are highly prevalent among patients with CHD, may decrease baseline levels of inflammation. Understanding the effects of physical activity on inflammation and insulin resistance in patients with CHD is important, as this population is at greatest cardiovascular risk and most likely to benefit from preventive interventions. Therefore, we conducted a prospective cohort study of outpatients with existing CHD to examine profiles of 5-year change in physical activity as predictors of inflammation and insulin resistance.

Methods

Participants were enrolled in the Heart and Soul Study, a cohort of outpatients with known CHD recruited from 2000 to 2002 from the San Francisco VA Medical Center, VA Palo Alto Health Care System, the University of California, San Francisco, Medical Center, and 9 public health clinics in the Community Health Network of San Francisco, California.² A total of 1,024 participants were enrolled in the original cohort. Eligible participants had documented CHD, defined as a history of myocardial infarction, coronary

^aDepartment of Medicine, University of California, San Francisco, San Francisco, California; ^bDepartment of Medicine, San Francisco VA Medical Center, San Francisco, California; and ^cCenter for Healthy Aging, Pennsylvania State University, University Park, Pennsylvania. Manuscript received April 4, 2014; revised manuscript received and accepted July 10, 2014.

Dr. Cohen was supported by Grant K23 HL 09476 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland, and Grant 12CRP11810021 from the American Heart Association, Dallas, Texas. Dr. Sin was supported by Institutional Training Grant T32 AG000212 from the National Institute on Aging, Bethesda, Maryland. The Heart and Soul Study was funded by the Department of Veterans Affairs, Washington, District of Columbia; grant R01 HL079235 from the National Heart, Lung, and Blood Institute; the American Federation for Aging Research (Paul Beeson Scholars Program), New York, New York; the Robert Wood Johnson Foundation (Faculty Scholars Program), Princeton, New Jersey; the Ischemia Research and Education Foundation, South San Francisco, California; and the Nancy Kirwan Heart Research Fund, San Francisco, California.

See page 1196 for disclosure information.

*Corresponding author: Tel: (415) 750-2093; fax: (415) 379-5573.

E-mail address: beth.cohen@ucsf.edu (B.E. Cohen).

revascularization, angiographic evidence of $\geq 50\%$ stenosis in ≥ 1 coronary vessel, or evidence of exercise-induced ischemia on a previous treadmill or nuclear stress test. Participants were excluded if they reported myocardial infarctions in the previous 6 months, were unable to walk 1 block, or were planning to move out of the local area within 3 years. Participants attended a baseline examination, which included a fasting blood draw, a physical examination, questionnaires, echocardiography, and a maximal exercise treadmill test. At 5 years, 667 participants (80% of the 829 survivors) completed a 5-year follow-up examination that repeated the baseline protocol, including a fasting blood draw. The present study was limited to 656 participants who had physical activity and biomarker assessments from the 2 time points. The study was approved by the appropriate institutional review boards, and all participants provided informed consent before enrollment.

Physical activity frequency was determined by self-report using the question "Which of the following statements best describes how physically active you have been during the last month, that is, done activities such as 15-20 minutes of brisk walking, swimming, general conditioning, or recreational sports?" Possible responses included "not at all active," "a little active (1-2 times per month)," "fairly active (3-4 times per month)," "quite active (1-2 times per week)," "very active (3-4 times per week)," and "extremely active (5 or more times per week)." Participants who answered "not at all active" or "a little active" were grouped into the low-activity group, whereas those who reported being "fairly active," "quite active," "very active," and "extremely active" were grouped into the high-activity group. This is consistent with previous classifications of physical activity in this cohort and has been shown to be a strong predictor of incident CHD events.² Single-item self-report measures of physical activity have also been shown to be valid and reliable measures of cardiovascular fitness.³⁻⁸ We used data from baseline and year 5 to categorize participants into 4 groups: (1) stable low activity included participants reporting low activity frequency at baseline and year 5, (2) decreasing activity included those with high activity frequency at baseline and low activity frequency at year 5, (3) increasing activity included those with low activity frequency at baseline and high activity frequency at year 5, and (4) stable high activity included those with high activity frequency at baseline and year 5.

Using baseline data, we also assessed the extent to which participants engaged in activities of different intensities within the past month for ≥ 15 to 20 minutes per episode, such as light-intensity activity (walking at an average pace, sweeping, vacuuming), moderate-intensity activity (brisk walking, lawn mowing, golf, dancing, light cycling), or heavy-intensity activity (swimming laps, basketball, jogging, vigorous cycling, hiking, or weightlifting). Possible responses were "not at all," "less than 1 time per week," "1-2 times per week," and "3 or more times per week."

Blood samples were collected after an overnight fast. High-sensitivity C-reactive protein (CRP) was measured using the Roche Integra assay (Roche Diagnostics, Indianapolis, Indiana) for the first 229 participants or (because of a change in the laboratory) the Beckman Extended Range assay (Beckman, Galway, Ireland). Results from the 2

assays were highly correlated ($r = 0.99$) in a sample of 189 participants. The interassay coefficients of variation were 3.2% for the Roche Integra assay and 6.7% for the Beckman Extended Range assay. A Quantikine High Sensitivity Immunoassay kit (R&D Systems, Minneapolis, Minnesota) was used to assess interleukin-6 serum concentration. The coefficient of variation for interleukin-6 ranged from 6.5% to 9.6%. Fibrinogen was measured using the Clauss assay, with a coefficient of variation of $< 3\%$. Fasting serum samples were used to measure glucose, insulin, glycated hemoglobin, total cholesterol, high-density lipoprotein cholesterol, and triglyceride concentrations. Low-density lipoprotein cholesterol concentrations were calculated.⁹

Age, gender, race and ethnicity, smoking status, highest educational achievement, and income level were determined by self-report. Co-morbidities were determined by asking if participants had ever received diagnoses from a list of medical conditions. Blood pressure, height, and weight were measured. Body mass index was calculated. All participants were instructed to bring in their current medication bottles for study personnel to record. Physical fitness was assessed by maximal exercise treadmill testing using a standard or modified Bruce protocol to determine maximal exercise capacity in METs.¹⁰ Rest and peak exercise 2-dimensional echocardiography was performed. Inducible ischemia was defined as the presence of new wall motion abnormalities at maximum exercise by an expert echocardiographer.

Other covariates were evaluated by self-report. Medication nonadherence was defined as taking medications $\leq 75\%$ of the time. Depressive symptoms were assessed using the 9-item Patient Health Questionnaire, and standard cut-point of ≥ 10 points was used to define depression.¹¹ Post-traumatic stress disorder was evaluated using the Computerized Diagnostic Interview Schedule for the *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition.¹²

Baseline characteristics were compared among the 4 physical activity groups using chi-square tests for categorical variables and Student's *t* tests for continuous variables. Biomarkers with abnormal distributions were log-transformed. Multivariate linear regression models were constructed with the 4 categories of physical activity as the independent variable and follow-up (year 5) inflammatory and insulin resistance biomarkers as the dependent variables. A test for trend was conducted across these models, with stable low activity as the reference group, followed by decreasing activity, increasing activity, and stable high activity. Adjustments were made for all variables that differed by physical activity status at $p \leq 0.10$. Smoking was also added to the models ($p = 0.11$) because of the known association with the predictor and the outcomes. Models were adjusted sequentially for baseline biomarker levels (model 1); then adding gender, education, chronic obstructive pulmonary disease, and aspirin use (model 2); followed by diabetes, use of any diabetes medications (specifically metformin, insulin, sulfonylureas, and thiazolidinediones), body mass index, and smoking (model 3); and finally depression and posttraumatic stress disorder (model 4). All values entered into the models were baseline values, as covariates did not substantially change within activity groups from baseline to year 5 (see "Results"). Statistical testing was 2 sided, at a significance level of 0.05. All

Table 1
Baseline characteristics by 5-year change in physical activity

Variable	Activity				p-Value
	Stable Low (N = 151)	Decreasing (N = 110)	Increasing (N = 60)	Stable High (N = 335)	
Age, Mean ± SD	65.4 ± 10.4	67.1 ± 10.8	64.7 ± 10.3	66.4 ± 9.8	0.36
Women	31 (21%)	21 (19%)	16 (27%)	44 (13%)	0.03
White	84 (56%)	65 (59%)	35 (58%)	210 (63%)	0.51
Graduated High School	124 (82%)	94 (86%)	48 (81%)	309 (92%)	<0.01
Diabetes Mellitus	41 (27%)	32 (29%)	11 (18%)	66 (20%)	0.09
Congestive Heart Failure	25 (17%)	19 (17%)	7 (12%)	45 (14%)	0.63
Myocardial Infarction	79 (52%)	55 (50%)	28 (47%)	179 (54%)	0.74
Chronic Obstructive Pulmonary Disease	28 (20%)	22 (21%)	8 (14%)	34 (11%)	0.02
Smoker	32 (21%)	23 (21%)	11 (18%)	45 (13%)	0.11
Medication Non-adherence	10 (7%)	10 (9%)	8 (13%)	18 (5%)	0.13
Body Mass Index (kg/m ²), Mean ± SD	30.1 ± 5.9	28.9 ± 5.7	28.3 ± 4.7	27.7 ± 4.3	<0.001
LDL (mg/dL), Mean ± SD	104.6 ± 33.1	106.3 ± 35.6	102.9 ± 32.6	103.6 ± 32.9	0.89
HDL (mg/dL), Mean ± SD	45.3 ± 14.4	46.6 ± 13.5	46.5 ± 16.2	47.1 ± 14.1	0.66
Systolic Blood Pressure (mmHg), Mean ± SD	134.1 ± 21.8	131.2 ± 19.7	136.3 ± 18.6	131.6 ± 20.0	0.26
Diastolic Blood Pressure (mmHg), Mean ± SD	75.1 ± 11.8	73.0 ± 11.7	77.2 ± 10.9	74.9 ± 10.6	0.11
Depression	49 (32%)	18 (16%)	16 (27%)	30 (9%)	<0.001
Posttraumatic Stress Disorder	27 (17.9%)	17 (15.5%)	8 (13.3%)	33 (9.9%)	0.08
Left Ventricular Ejection Fraction <40%	20 (13%)	7 (6%)	5 (8%)	34 (10%)	0.31
Fitness (METs), Mean ± SD	6.5 ± 2.5	6.7 ± 2.8	7.2 ± 3.1	9.1 ± 3.2	<0.001
Inducible Ischemia	30 (21%)	25 (26%)	8 (15%)	56 (17%)	0.25
Aspirin	101 (68%)	87 (80%)	41 (69%)	254 (76%)	0.10
Statins	97 (65%)	76 (70%)	42 (71%)	237 (71%)	0.62
Renin Angiotensin System Inhibitor	80 (54%)	54 (50%)	23 (39%)	173 (52%)	0.26
Beta Blockers	88 (59%)	68 (62%)	34 (58%)	190 (57%)	0.78
Any Diabetes Medication*	35 (23%)	27 (25%)	11 (18%)	42 (13%)	0.01

CRP = C-reactive protein; HDL = high density lipoprotein; LDL = low density lipoprotein.

* Includes: sulfonylureas, insulin, metformin, thiazolidinediones.

Table 2
Median levels of biomarkers by activity group at baseline and 5-year follow up

Biomarker	Activity				p-Value for Trend
	Stable Low	Decreasing	Increasing	Stable High	
CRP (mg/L)					
Baseline	3.08	1.75	2.37	1.63	<0.001
Follow-up	2.16	1.93	1.65	1.15	<0.001
5-year change (% change)	-0.92 (-30%)	0.18 (+10%)	-0.72 (-30%)	-0.48 (-29%)	
Interleukin-6 (pg/mL)					
Baseline	2.90	2.44	2.73	2.11	<0.001
Follow-up	4.18	4.23	3.46	2.83	<0.001
5-year change (% change)	1.28 (+44%)	1.79 (+73%)	0.73 (+27%)	0.72 (+34%)	
Fibrinogen (RU/mL)					
Baseline	393	376	389	363	<0.01
Follow-up	382	372	373	357	0.01
5-year change (% change)	-11 (-3%)	-4 (-1%)	-16 (-4%)	-6 (-2%)	
Insulin (pg/mL)					
Baseline	296	286	272	269	0.25
Follow-up	255	250	228	215	0.08
5-year change (% change)	-41 (-14%)	-36 (-13%)	-44 (-16%)	-54 (-20%)	
Glucose (mg/dL)					
Baseline	108	108	107	105	0.23
Follow-up	106	108	102	104	0.01
5-year change (% change)	-2 (-2%)	0 (0)	-5 (-5%)	-1 (-1%)	
Hemoglobin A1c (%)					
Baseline	5.8	5.8	5.7	5.6	0.02
Follow-Up	5.8	5.7	5.6	5.6	0.01
5-year change (% change)	0 (0)	-0.1 (-2%)	-0.1 (-2%)	0 (0)	

CRP = C-reactive protein.

Table 3
Differences in Year 5 inflammatory biomarker levels as compared with the stable low group

Variable	Activity			p-Value for Trend
	Decreasing	Increasing	Stable High	
Log CRP	β (95% CI)			
Model 1	-0.07 (-0.34, 0.20)	-0.24 (-0.57, 0.08)	-0.25 (-0.46, -0.03)	0.01
Model 2	-0.07 (-0.34, 0.21)	-0.24 (-0.57, 0.09)	-0.24 (-0.46, -0.02)	0.02
Model 3	-0.05 (-0.33, 0.22)	-0.21 (-0.54, 0.13)	-0.24 (-0.46, -0.02)	0.02
Model 4	-0.05 (-0.33, 0.23)	-0.20 (-0.53, 0.14)	-0.23 (-0.46, -0.001)	0.03
Log Interleukin-6	β (95% CI)			
Model 1	0.09 (-0.05, 0.24)	-0.08 (-0.25, 0.10)	-0.14 (-0.26, -0.03)	0.003
Model 2	0.08 (-0.07, 0.23)	-0.08 (-0.26, 0.10)	-0.15 (-0.27, -0.03)	0.002
Model 3	0.08 (-0.06, 0.23)	-0.07 (-0.25, 0.11)	-0.14 (-0.26, -0.02)	0.01
Model 4	0.09 (-0.06, 0.24)	-0.06 (-0.24, 0.12)	-0.13 (-0.25, -0.003)	0.01
Fibrinogen	β (95% CI)			
Model 1	-14.40 (-33.67, 4.87)	-17.44 (-40.52, 5.63)	-16.82 (-31.88, -1.76)	0.04
Model 2	-13.70 (-33.26, 5.87)	-16.78 (-40.4, 6.84)	-16.86 (-32.30, -1.43)	0.05
Model 3	-14.34 (-33.94, 5.26)	-15.42 (-39.18, 8.34)	-15.15 (-30.90, 0.60)	0.09
Model 4	-12.51 (-32.30, 7.29)	-14.52 (-38.33, 9.29)	-12.32 (-28.61, 3.97)	0.16

Model 1 = Adjusted for baseline biomarker level.

Model 2 = Adjusted for above + gender, baseline education, chronic obstructive pulmonary disease, and aspirin use.

Model 3 = Adjusted for above + baseline diabetes, BMI, diabetes medications, and smoking.

Model 4 = Adjusted for above + baseline depression, and posttraumatic stress disorder.

CI = confidence interval; CRP = C-reactive protein.

Table 4
Differences in Year 5 insulin resistance biomarker levels as compared with the stable low group

Variable	Activity			p-Value for Trend
	Decreasing	Increasing	Stable High	
Log Insulin	β (95% CI)			
Model 1	-0.10 (-0.26, 0.05)	-0.13 (-0.32, 0.06)	-0.10 (-0.22, 0.03)	0.14
Model 2	-0.12 (-0.28, 0.03)	-0.15 (-0.34, 0.04)	-0.10 (-0.23, 0.02)	0.12
Model 3	-0.07 (-0.22, 0.08)	-0.08 (-0.27, 0.10)	-0.05 (-0.18, 0.07)	0.40
Model 4	-0.08 (-0.23, 0.07)	-0.09 (-0.27, 0.10)	-0.07 (-0.19, 0.06)	0.32
Log Glucose	β (95% CI)			
Model 1	-0.01 (-0.06, 0.03)	-0.08 (-0.13, -0.02)	-0.04 (-0.08, -0.003)	0.005
Model 2	-0.01 (-0.06, 0.03)	-0.07 (-0.13, -0.01)	-0.05 (-0.08, -0.01)	0.003
Model 3	-0.01 (-0.06, 0.03)	-0.07 (-0.12, -0.01)	-0.04 (-0.08, -0.01)	0.005
Model 4	-0.02 (-0.06, 0.03)	-0.07 (-0.12, -0.01)	-0.05 (-0.08, -0.01)	0.003
Hemoglobin A1c	β (95% CI)			
Model 1	0.13 (-0.06, 0.32)	-0.01 (-0.24, 0.22)	-0.04 (-0.19, 0.11)	0.32
Model 2	0.13 (-0.06, 0.33)	-0.01 (-0.24, 0.23)	-0.03 (-0.19, 0.12)	0.38
Model 3	0.15 (-0.03, 0.34)	0.04 (-0.19, 0.27)	0.02 (-0.13, 0.17)	0.82
Model 4	0.15 (-0.04, 0.33)	0.03 (-0.19, 0.26)	0.003 (-0.15, 0.16)	0.70

Model 1 = Adjusted for baseline biomarker level.

Model 2 = Adjusted for above + gender, baseline education, chronic obstructive pulmonary disease, and aspirin use.

Model 3 = Adjusted for above + baseline diabetes, BMI, and smoking.

Model 4 = Adjusted for above + baseline depression, and posttraumatic stress disorder.

CI = confidence interval.

analyses were conducted using SAS version 9.3 (SAS Institute Inc., Cary, North Carolina).

Results

A total of 656 participants were included in the study, with a mean age of 66.1 ± 10.2 years. Sixty percent of participants were white, and 83% were men. Baseline characteristics by physical activity group are listed in

Table 1. Cardiovascular medication use was similar across groups. Use of diabetes medications differed across activity groups despite a nonsignificant difference in rates of diabetes. Notably, mean measured exercise capacity corresponded well with self-reported activity status. Reported levels of light-, moderate-, and heavy-intensity activity at baseline are shown in [Supplementary Figure 1](#). Most activities reported were of light and moderate intensity. Even in the stable high activity group, <20% reported

engaging in heavy-intensity activity ≥ 3 times per week. Among the entire cohort, only 73 participants (11%) reported engaging in heavy-intensity activities ≥ 3 times per week.

Median values of biomarkers at baseline and after 5 years of follow-up in each physical activity group are listed in Table 2. There were significant inverse trends between inflammation and insulin resistance biomarkers and physical activity group at baseline and 5-year follow-up. Nearly all groups were observed to have decreasing or unchanged levels of biomarkers at 5 years, with the exception of interleukin-6. The groups with the lowest activity had the largest increase in interleukin-6.

The relation between change in physical activity over time and levels of biomarkers at 5-year follow-up are listed in Tables 3 and 4. Log CRP remained inversely associated with activity level in the fully adjusted model (p for trend across activity groups = 0.03; Table 3). Similar results were seen for log interleukin-6 (p for trend = 0.01). Of the markers for insulin resistance, only glucose achieved significance and remained so in the fully adjusted model (p for trend = 0.003; Table 4).

For the covariates adjusted for in the regression analysis, we evaluated for differences in baseline and 5-year follow-up rates within each of the 4 activity groups. No significant differences were seen in rates of depression or aspirin use or in body mass index between baseline and 5-year follow-up within any activity group. Differences in other covariates were modest and occurred in a minority of the activity groups. Smoking decreased at 5-year follow-up in the stable high activity group (from 13.5% to 10.8%, $p = 0.03$), and rates of diabetes increased in the decreasing activity group (from 29.1% to 37.3%, $p = 0.02$) and the stable high activity group (from 19.7% to 25.7%, $p < 0.001$). Higher rates of chronic obstructive pulmonary disease were also reported at 5-year follow-up in the decreasing activity group (20.0% to 25.7%, $p = 0.04$).

Discussion

In a prospective study of outpatients with known CHD and high rates of statin and aspirin use, a higher frequency of physical activity was independently associated with lower levels of CRP, interleukin-6, and glucose at 5-year follow-up. Overall, levels of vigorous physical activity were low, with few patients reporting participation in moderate- or heavy-intensity physical activity ≥ 3 times per week. These data suggest that even light-intensity activity may be beneficial for reducing or maintaining lower levels of inflammation in a medically complex population.

Our results expand on previous studies examining the biologic impact of physical activity. Using a community-based sample, the Whitehall II cohort study¹ followed >4,000 apparently healthy middle-aged men and women over 10 years and monitored self-reported adherence to physical activity guidelines and markers of inflammation (i.e., CRP and interleukin-6). The investigators found that the high adherence group had lower log CRP levels and lower log interleukin-6 levels at follow-up. However, these patients were generally disease free and were on average almost 20 years younger than our study cohort.

Within our study, patients with greater frequency of physical activity over time had lower mean levels of insulin resistance biomarkers, although associations with insulin and glycated hemoglobin were not significant after adjusting for baseline values. Observations from previous studies have shown that regular physical activity improves insulin resistance through multiple metabolic and vascular processes^{13,14} and that these pathways often work in concert to improve a patient's cardiovascular risk. However, observations from obese children have shown that the benefits are short lived after the cessation of regular physical activity, lasting only weeks to months.¹⁵ This may explain why participants whose physical activity decreased over 5 years had insulin resistance biomarker levels similar to those in the stable low activity group.

In contrast to previous studies, which have shown increases in inflammatory biomarkers with age, CRP and fibrinogen were lower at follow-up in our population.¹⁶ Participants in our study had known CHD, and therapies aimed at reducing their risk for further events could have lowered inflammatory levels. For example, statin trials have shown that CRP decreases over time with continued statin therapy,¹⁷ and our findings could reflect the long-term effect of high statin use in our population. It is also possible that statin therapy was intensified during the study period, as the timeline corresponds with updated guidelines recommending more aggressive low-density lipoprotein goals.¹⁸

Although this is the first study of its kind in outpatients with CHD, there were several limitations that should be considered. First, given that only those participants who survived to 5-year follow-up were included, our study population may have been healthier than the full baseline cohort, although we would expect this to diminish the variability in inflammation and insulin resistance. Second, physical activity data were self-reported and may have been susceptible to recall or response biases. However, self-reported physical activity has been shown to correspond to objective measures,^{3,5,7} and it correlated highly with objectively measured physical fitness within this study. Third, this cohort had stable CHD and was predominantly male, thereby limiting generalizability to women and other populations. Finally, dietary patterns have been shown to influence levels of inflammatory biomarkers and risk of incident diabetes,^{19,20} but no diet information was obtained in this study. The interaction of diet and physical activity and their effect on biomarkers would be an important topic for future studies.

Disclosures

The authors have no conflicts of interest to disclose.

Supplementary Data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.amjcard.2014.07.036>.

1. Hamer M, Sabia S, Batty D, Shipley MJ, Tabak AG, Singh-Manoux A, Kivimaki M. Physical activity and inflammatory markers over 10 years: follow-up in men and women from the Whitehall II cohort study. *Circulation* 2012;126:928–933.

2. Whooley MA, Jonge Pd, Vittinghoff E, Otte C, Moos R, Carney RM, Ali S, Dowray S, Na B, Feldman MD, Schiller NB, Browner WS. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. *JAMA* 2008;300:2379–2388.
3. Bowles HR, Fitzgerald SJ, Morrow JRJ, Jackson AW, Blair SN. Construct validity of self-reported historical physical activity. *Am J Epidemiol* 2004;160:279–286.
4. Ainsworth BE, Jacobs DR, Leon AS. Validity and reliability of self-reported physical activity status: the Lipid Research Clinics Questionnaire. *Med Sci Sports Exerc* 1993;25:92–98.
5. Aadahl M, Kjaer M, Kristensen JH, Mollerup B, Jorgensen T. Self-reported physical activity compared with maximal oxygen uptake in adults. *Eur J Cardiovasc Prev Rehabil* 2007;14:422–428.
6. Jackson AW, Morrow JRJ, Bowles HR, Fitzgerald SJ, Blair SN. Construct validity evidence for single-response items to estimate physical activity levels in large sample studies. *Res Q Exerc Sport* 2007;78:24–31.
7. Knapik J, Zoltick J, Rottner HC, Phillips J, Bielenda C, Jones B, Drews F. Relationships between self-reported physical activity and physical fitness in active men. *Am J Prev Med* 1993;9:203–208.
8. Vanhees L, Lefevre J, Philippaerts R, Martens M, Huygens W, Troosters T, Beunen G. How to assess physical activity? How to assess physical fitness? *Eur J Cardiovasc Prev Rehabil* 2013;12:102–114.
9. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972;18:499–502.
10. Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, Whooley MA. Depressive symptoms and health-related quality of life—the Heart and Soul Study. *JAMA* 2003;290:215–221.
11. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med* 2001;16:606–613.
12. Cohen BE, Marmar CR, Neylan TC, Schiller NB, Ali S, Whooley MA. Posttraumatic stress disorder and health-related quality of life in patients with coronary heart disease: findings from the Heart and Soul Study. *Arch Gen Psychiatry* 2009;66:1214–1220.
13. Ross R, Janssen I, Dawson J, Kung A-M, Kuk JL, Wong SL, Nguyen-Duy T-B, Lee S, Kilpatrick K, Hudson R. Exercise-induced reduction in obesity and insulin resistance in women: a randomized controlled trial. *Obesity* 2004;12:789–798.
14. Ivy JL. Role of exercise training in the prevention and treatment of insulin resistance and non-insulin-dependent diabetes mellitus. *Sports Med* 1997;24:321–336.
15. Ferguson MA, Gutin B, Le NA, Karp W, Litaker M, Humphries M, Okuyama T, Riggs S, Owens S. Effects of exercise training and its cessation on components of the insulin resistance syndrome in obese children. *Int J Obes Relat Metab Disord* 1999;23:889–895.
16. Ferrucci L, Corsi A, Lauretani F, Bandinelli S, Bartali B, Taub DD, Guralnik JM, Longo DL. The origins of age-related proinflammatory state. *Blood* 2005;105:2294–2299.
17. Nissen SE, Tuzcu M, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O’Shaughnessy C, Ganz P, Investigators R. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. *N Engl J Med* 2005;352:29–38.
18. Grundy SM, Cleeman JI, Merz CNB, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Program for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation* 2004;110:227–239.
19. Consortium TI. Consumption of sweet beverages and type 2 diabetes incidence in European adults: results from EPIC-InterAct. *Diabetologia* 2013;56:1520–1530.
20. Meyer J, Doring A, Herder C, Roden M, Koenig W, Thorand B. Dietary patterns, subclinical inflammation, incident coronary heart disease and mortality in middle-aged men from the MONICA/KORA Augsburg cohort study. *Eur J Clin Nutr* 2011;65:800–807.